特殊非專利市場規模、佔有率和成長分析（按類型、應用、分銷管道和地區）- 產業預測 2025-2032

預計特種非專利市場規模將在 2023 年達到 824 億美元，並從 2024 年的 905.6 億美元成長到 2032 年的 1927.1 億美元，預測期內（2025-2032 年）的複合年成長率為 9.9%。

全球特種非專利市場專注於針對特定疾病的獨特的、專利到期藥物，由於對品牌藥物的平價替代品的需求不斷增加、專利到期和控制醫療成本的努力，該市場正在經歷顯著成長。儘管面臨配方複雜、治療領域多樣和監管障礙等挑戰，但該市場仍因能夠提供具有成本效益的治療方法而提供了機會。製藥公司優先考慮市場開發、生產和合規，同時也建立策略聯盟和收購以加強其市場地位。醫療政策變化、定價壓力和藥物傳輸技術進步將進一步影響市場的發展，最終影響創新和可及治療方法的可用性。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管分析

特殊非專利市場規模（按類型和複合年成長率） (2025-2032)

• 市場概況
• 注射
• 口服藥物

特殊非專利市場規模（按應用分類）及複合年成長率（2025-2032）

• 市場概況
• 腫瘤學
• 發炎性疾病
• C型肝炎
• 多發性硬化症
• 其他用途

特殊非專利市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 專業藥房
• 零售藥局
• 醫院藥房
• 其他分銷管道

特殊非專利市場規模（按地區分類）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Teva Pharmaceuticals（Israel）
• Sandoz（Switzerland）
• Sun Pharma（India）
• Viatris（United States）
• Biocon（India）
• Aurobindo Pharma（India）
• Fresenius Kabi（Germany）
• Cipla（India）
• Dr. Reddy's Laboratories（India）
• Aspen（South Africa）
• Lupin（India）
• Mallinckrodt（Ireland）
• Zydus（India）
• KRKA（Slovenia）
• Glenmark（India）
• Stada（Germany）
• Amneal（United States）
• Towa（Japan）
• Sawai（Japan）
• Hikma（Jordan）

結論和建議

Specialty Generics Market size was valued at USD 82.4 billion in 2023 and is poised to grow from USD 90.56 billion in 2024 to USD 192.71 billion by 2032, growing at a CAGR of 9.9% during the forecast period (2025-2032).

The global specialty generics market, which focuses on unique off-patent medications for specific conditions, is experiencing significant growth driven by the increasing demand for affordable alternatives to brand-name drugs, the expiration of patents, and efforts to control healthcare costs. This market presents opportunities through its ability to provide cost-effective treatments, although it faces challenges such as complex formulations, a variety of therapeutic areas, and regulatory barriers. Pharmaceutical companies are prioritizing development, production, and compliance while engaging in strategic partnerships and acquisitions to enhance their market positions. The market's evolution is further shaped by changing healthcare policies, pricing pressures, and advancements in drug delivery technologies, ultimately influencing the availability of innovative and accessible therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Specialty Generics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Specialty Generics Market Segments Analysis

Global Specialty Generics Market is segmented by Type, Application, Distribution Channel and region. Based on Type, the market is segmented into Injectables and Oral Drugs. Based on Application, the market is segmented into Oncology, Inflammatory Conditions, Hepatitis C, Multiple Sclerosis and Other Applications. Based on Distribution Channel, the market is segmented into Specialty Pharmacy, Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Specialty Generics Market

The specialty generics market is primarily driven by the increasing demand for cost-effective alternatives to brand-name specialty medications. These generics offer a more affordable solution for patients and healthcare providers, particularly in light of rising healthcare expenses. As more individuals seek budget-friendly treatment options for complex and chronic conditions, the appeal of specialty generics continues to grow. This demand underscores the importance of providing accessible medication solutions, thereby fueling the expansion of the specialty generics market as it aligns with the overall goal of making healthcare more affordable and manageable for a broader range of patients.

Restraints in the Specialty Generics Market

The Specialty Generics market faces significant constraints due to the intricate nature of its formulations, delivery systems, and manufacturing methods. The production and development of these medications necessitate a high level of specialized knowledge and infrastructure, which can be a barrier for many manufacturers. As a result, this complexity restricts the number of companies equipped to create specialty generics, potentially resulting in supply shortages. The challenges associated with producing these advanced medications underscore the need for substantial investment and expertise, ultimately limiting the overall availability and accessibility of specialty generics in the market.

Market Trends of the Specialty Generics Market

The Specialty Generics market is experiencing a robust trend towards complex generics, driven by an increasing demand for advanced medications that offer significant therapeutic benefits at reduced costs. These generics, characterized by their intricate formulations and sophisticated delivery systems, are gaining traction due to their ability to effectively address conditions like cancer, central nervous system disorders, and autoimmune diseases. As healthcare providers and patients seek more tailored treatment options, the need for expertise and innovation in developing products such as extended-release formulations, inhalation devices, and biosimilars is rising. This shift is fostering investment and driving growth in the specialty generics sector, promising substantial market potential.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Specialty Generics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Injectables
• Oral Drugs

Global Specialty Generics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Oncology
• Inflammatory Conditions
• Hepatitis C
• Multiple Sclerosis
• Other Applications

Global Specialty Generics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Specialty Pharmacy
• Retail Pharmacy
• Hospital Pharmacy
• Other Distribution Channels

Global Specialty Generics Market Size & CAGR (2025-2032)

• North America (Type, Application, Distribution Channel)
  • US
  • Canada
• Europe (Type, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Teva Pharmaceuticals (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspen (South Africa)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KRKA (Slovenia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stada (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Towa (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sawai (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma (Jordan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations